Los 3 mil candidatos para ser voluntarios del ensayo clínico de la vacuna china de Sinopharm contra la COVID-19 fue copado en tan solo 11 minutos. E profesor principal de la Cayetano Heredia, Germán Málaga, dijo que la afluencia de visitas en la página web fue alta. La inscripción de un segundo grupo de 3 mil candidatos se abrirá en los próximos días. Fuente: [América TV]
:quality(75)/cdn.jwplayer.com/v2/media/Q6eEUBax/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/08-31-2020/t_5a15f642f5324adeabba28631924804f_name_C04_VACUNA.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/3inaY770/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/VsboS0Ds/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/4XJYWHUXTZENLOPBNOGTADBRKU.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/VsboS0Ds/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/GN8jAoBx/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/UZD65mZH/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/avGXOsZ4/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/RiJl8E7C/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/lcJYjzTu/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/WVUXO4EV2ZFZVDLFIKR2LU5PZU.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/whZALDRw/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Q6eEUBax/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/4XJYWHUXTZENLOPBNOGTADBRKU.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/BWFPLD4WB5FOTCHEJNZAB636LQ.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/MY72IZA3BVBVZKPNKM44H4ZXAI.png)
:quality(75)/cdn.jwplayer.com/v2/media/3inaY770/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/zU1kkc1N/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/woE0RipK/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/fXfJig3r/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/76OSI7ELWBE6ZHGIL4UT7FMBGI.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5MX44LCM7BFEVHZQU33WFPMZFE.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/aIjZ5WWB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QYPNFGK56RE7FB6OYBZFBZOR6M.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/8j1uxDqb/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ZxUTUGfS/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)